{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:19:07Z","timestamp":1771431547747,"version":"3.50.1"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cabotegravir plus rilpivirine long-acting (CAB + RPV-LA) injectable therapy marks a major milestone in HIV care, offering an efficacious, well-tolerated alternative to daily oral antiretroviral treatment. This article reviews data from pivotal trials and observational studies of CAB + RPV-LA, addressing emerging questions and highlighting key research priorities. We examine factors influencing virological outcomes, including issues related to HIV subtype, archived drug resistance, body mass index, and pharmacokinetics, and discuss challenges related to hepatitis B virus immunity and infection, pregnancy, and adherence. We outline strategies to address barriers to implementation, advocating for a tailored approach to maximize the potential of CAB + RPV-LA in improving outcomes across diverse populations with HIV.<\/jats:p>","DOI":"10.1093\/ofid\/ofaf368","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T07:59:37Z","timestamp":1750319977000},"source":"Crossref","is-referenced-by-count":5,"title":["Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3670-6588","authenticated-orcid":false,"given":"Anna Maria","family":"Geretti","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata , Rome ,","place":["Italy"]},{"name":"Department of Infection, Royal Free London NHS Foundation Trust\u2014North Mid , London ,","place":["UK"]},{"name":"School of Immunity & Microbial Sciences, King's College London , London ,","place":["UK"]}]},{"given":"Marta","family":"Boffito","sequence":"additional","affiliation":[{"name":"St Stephens and Department of Infectious Diseases, Chelsea and Westminster Hospital and Imperial College London , London ,","place":["UK"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7537-3341","authenticated-orcid":false,"given":"Stefano","family":"Bonora","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, University of Torino , Torino ,","place":["Italy"]}]},{"given":"Patrick","family":"Braun","sequence":"additional","affiliation":[{"name":"PZB Aachen, Laboratory Knechten , Aachen ,","place":["Germany"]},{"name":"InXFo GmbH , Hamburg ,","place":["Germany"]}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"Service de Virologie, H\u00f4pital Bichat-Claude Bernard, AP-HP , Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMR 1137 IAME , Paris ,","place":["France"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-781X","authenticated-orcid":false,"given":"Federico","family":"Garcia","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda Cl\u00ednica, Hospital Universitario Cl\u00ednico San Cecilio \u00a0 Granada ,","place":["Spain"]},{"name":"Ciber de Enfermedades Infecciosas, CIBERINFEC , Madrid ,","place":["Spain"]},{"name":"Instituto de Investigaci\u00f3n Biosanitaria Ibs.GRANADA , Granada ,","place":["Spain"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-959X","authenticated-orcid":false,"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[{"name":"Assistance Publique\u2014H\u00f4pitaux de Paris.Nord, H\u00f4pital Bichat Claude Bernard, Service des Maladies Infectieuses et Tropicales , Paris ,","place":["France"]},{"name":"Universit\u00e9 paris Cit\u00e9, INSERM UMR 1137 IAME, Facult\u00e9 de M\u00e9decine site Bichat , Paris ,","place":["France"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3271-8255","authenticated-orcid":false,"given":"Perpetua","family":"Gomes","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Biologia Molecular (LMCBM, SPC, HEM, ULS-LO) \u00a0 Lisboa ,","place":["Portugal"]},{"name":"Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science , Caparica, Almada ,","place":["Portugal"]}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, UMR_S 1136 Pierre Louis Institute of Epidemiology and Public Health, AP-HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, Laboratoire de Virologie , Paris ,","place":["France"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0515-9128","authenticated-orcid":false,"given":"Thibault","family":"Mespl\u00e8de","sequence":"additional","affiliation":[{"name":"Viroscience Department, Erasmus University Medical Center , Rotterdam ,","place":["The Netherlands"]}]},{"given":"Milosz","family":"Parczewski","sequence":"additional","affiliation":[{"name":"Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin , Szczecin ,","place":["Poland"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4016-4643","authenticated-orcid":false,"given":"Kyle","family":"Ring","sequence":"additional","affiliation":[{"name":"SHARE Collaborative, Blizard Institute, Queen Mary University of London , London ,","place":["UK"]},{"name":"Department of Sexual Health, Barts Health NHS Trust , London ,","place":["UK"]}]},{"given":"Maria Mercedes","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome Tor Vergata , Rome ,","place":["Italy"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0943-9648","authenticated-orcid":false,"given":"Caroline","family":"Solas","sequence":"additional","affiliation":[{"name":"Laboratoire de Pharmacocin\u00e9tique et Toxicologie, AP-HM, H\u00f4pital La Timone , Marseille ,","place":["France"]},{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE: Aix-Marseille Univ, Universit\u00e0 di Corsica, IRD 190, Inserm 1207, IRBA) , Marseille ,","place":["France"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1678-8520","authenticated-orcid":false,"given":"Eva","family":"Wolf","sequence":"additional","affiliation":[{"name":"Clinical Research, MUC Research GmbH , Eurofins, Munich ,","place":["Germany"]},{"name":"Clinical Research, MVZ M\u00fcnchen am Goetheplatz , Munich ,","place":["Germany"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6168-6745","authenticated-orcid":false,"given":"Chloe","family":"Orkin","sequence":"additional","affiliation":[{"name":"SHARE Collaborative, Blizard Institute, Queen Mary University of London , London ,","place":["UK"]},{"name":"Department of Sexual Health, Barts Health NHS Trust , London ,","place":["UK"]}]}],"member":"286","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"2026021810420176300_ofaf368-B1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0000000000003025","article-title":"Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment","volume":"36","author":"Swindells","year":"2022","journal-title":"AIDS"},{"key":"2026021810420176300_ofaf368-B2","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1016\/S2352-3018(21)00184-3","article-title":"Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"2026021810420176300_ofaf368-B3","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2\u2005M, a randomized, open-label, phase 3b, noninferiority study","volume":"76","author":"Overton","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026021810420176300_ofaf368-B4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society\u2013USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2026021810420176300_ofaf368-B5","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jama.2024.2985","article-title":"IAS-USA treatment guidelines panel. Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA Guidelines Panel","volume":"331","author":"Sax","year":"2024","journal-title":"JAMA"},{"key":"2026021810420176300_ofaf368-B6","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2026021810420176300_ofaf368-B7","author":"European AIDS Clinical Society"},{"key":"2026021810420176300_ofaf368-B8","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/cid\/ciad370","article-title":"Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure","volume":"77","author":"Orkin","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026021810420176300_ofaf368-B9","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","article-title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial","volume":"10","author":"Ramgopal","year":"2023","journal-title":"Lancet HIV"},{"key":"2026021810420176300_ofaf368-B10","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","article-title":"Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial","volume":"24","author":"Kityo","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026021810420176300_ofaf368-B11","author":"Kityo"},{"key":"2026021810420176300_ofaf368-B12","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3390\/v12080838","article-title":"Genetic features of HIV-1 integrase sub-subtype A6 predominant in Russia and predicted susceptibility to INSTIs","volume":"12","author":"Kirichenko","year":"2020","journal-title":"Viruses"},{"key":"2026021810420176300_ofaf368-B13","doi-asserted-by":"crossref","first-page":"e0260604","DOI":"10.1371\/journal.pone.0260604","article-title":"Origin and evolution of HIV-1 subtype A6","volume":"16","author":"Abidi","year":"2021","journal-title":"PLoS One"},{"key":"2026021810420176300_ofaf368-B14","author":"Stanford University HIV Drug Resistance Database"},{"key":"2026021810420176300_ofaf368-B15","doi-asserted-by":"crossref","first-page":"e0170221","DOI":"10.1128\/aac.01702-21","article-title":"Impact of integrase sequences from HIV-1 subtypes A6\/A1 on the in vitro potency of cabotegravir or rilpivirine","volume":"66","author":"Jeffrey","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021810420176300_ofaf368-B16","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/infdis\/jiad291","article-title":"Effect of the L74I polymorphism on fitness of cabotegravir-resistant variants of HIV-1 subtype A6","volume":"228","author":"Hu","year":"2023","journal-title":"J Infect Dis"},{"key":"2026021810420176300_ofaf368-B17","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1093\/cid\/ciad058","article-title":"Circulation of HIV-1 A6 variant in the east border of European Union\u2014dynamics of the virus transmissions between Poland and Ukraine","volume":"76","author":"Serwin","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026021810420176300_ofaf368-B18","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s40121-022-00676-y","article-title":"HIV DNA sequencing to detect archived antiretroviral drug resistance","volume":"11","author":"Geretti","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2026021810420176300_ofaf368-B19","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/jac\/dkae007","article-title":"Use of genotypic HIV DNA testing: a DELPHI-type consensus","volume":"79","author":"Andre-Garnier","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026021810420176300_ofaf368-B20","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/QAD.0000000000002850","article-title":"Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation","volume":"35","author":"Li","year":"2021","journal-title":"AIDS"},{"key":"2026021810420176300_ofaf368-B21","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1086\/496892","article-title":"Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection","volume":"192","author":"Deeks","year":"2005","journal-title":"J Infect Dis"},{"key":"2026021810420176300_ofaf368-B22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.virol.2010.03.018","article-title":"The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations","volume":"402","author":"Wang","year":"2010","journal-title":"Virology"},{"key":"2026021810420176300_ofaf368-B23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/15284336.2015.1115585","article-title":"Clinical outcomes of virologically-suppressed patients with pre-existing HIV-1 drug resistance mutations switching to rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate in the SPIRIT study","volume":"17","author":"Porter","year":"2016","journal-title":"HIV Clin Trials"},{"key":"2026021810420176300_ofaf368-B24","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/infdis\/jiad580","article-title":"Efficacy, safety, and pharmacokinetics by body mass index category in phase 3\/3b long-acting cabotegravir plus rilpivirine trials","volume":"230","author":"Elliot","year":"2024","journal-title":"J Infect Dis"},{"key":"2026021810420176300_ofaf368-B25","author":"Eu"},{"key":"2026021810420176300_ofaf368-B26","first-page":"ciae579","article-title":"Real world virologic outcomes in patients with elevated body mass index receiving long acting cabotegravir\/rilpivirine","author":"Maguire","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026021810420176300_ofaf368-B27","author":"Sension"},{"key":"2026021810420176300_ofaf368-B28","author":"Troya"},{"key":"2026021810420176300_ofaf368-B29","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/cid\/ciae475","article-title":"Virological history predicts non-sustained viral suppression with long-acting cabotegravir and rilpivirine therapy, independent of pharmacokinetic parameters","volume":"80","author":"Guti\u00e9rrez","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026021810420176300_ofaf368-B30","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S1473-3099(15)00152-8","article-title":"Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial","volume":"15","author":"Margolis","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2026021810420176300_ofaf368-B31","author":"N\u00e9ant"},{"key":"2026021810420176300_ofaf368-B32","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae023","article-title":"Guidance for the interpretation of long-acting cabotegravir and rilpivirine concentrations based on real-world therapeutic drug monitoring data and documented failures","volume":"11","author":"Thoueille","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026021810420176300_ofaf368-B33","doi-asserted-by":"crossref","first-page":"100793","DOI":"10.1016\/j.lanepe.2023.100793","article-title":"Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland","volume":"36","author":"Thoueille","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026021810420176300_ofaf368-B34","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1093\/jac\/dkae308","article-title":"Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror phase 3 results","volume":"79","author":"Serris","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026021810420176300_ofaf368-B35","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/QAD.0000000000003887","article-title":"Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine","volume":"38","author":"Rubenstein","year":"2024","journal-title":"AIDS"},{"key":"2026021810420176300_ofaf368-B36","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/cid\/ciae060","article-title":"Effect of obesity on the exposure of long-acting cabotegravir and rilpivirine: a modeling study","volume":"79","author":"Bettonte","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026021810420176300_ofaf368-B37","author":"Ghosn"},{"key":"2026021810420176300_ofaf368-B38","author":"Committee Antiretroviral Pregnancy Registry (APR)"},{"key":"2026021810420176300_ofaf368-B39","author":"Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission"},{"key":"2026021810420176300_ofaf368-B40","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/hiv.13439","article-title":"Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials","volume":"24","author":"Patel","year":"2023","journal-title":"HIV Med"},{"key":"2026021810420176300_ofaf368-B41","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/cid\/ciae242","article-title":"Cabotegravir and rilpivirine long acting injectables in a pregnant woman living with HIV","volume":"79","author":"van der Wekken-Pas","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026021810420176300_ofaf368-B42","author":"Delany-Moretlwe"},{"key":"2026021810420176300_ofaf368-B43","author":"Short"},{"key":"2026021810420176300_ofaf368-B44","author":"Atoyebi"},{"key":"2026021810420176300_ofaf368-B45","author":"Yu"},{"key":"2026021810420176300_ofaf368-B46","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/bcp.16006","article-title":"Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy","volume":"91","author":"Atoyebi","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"2026021810420176300_ofaf368-B47","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cid\/ciae331","article-title":"Interest in and preference for long-acting injectable antiretroviral therapy in the era of approved cabotegravir\/rilpivirine among reproductive-aged women in the U.S. South","volume":"80","author":"Collins","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"2026021810420176300_ofaf368-B48","first-page":"s2","article-title":"British HIV Association guidelines on the use of vaccines in HIV-positive adults","volume":"17","author":"Geretti","year":"2016","journal-title":"HIV Med"},{"key":"2026021810420176300_ofaf368-B49","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.3748\/wjg.v28.i31.4249","article-title":"Insights into induction of the immune response by the hepatitis B vaccine","volume":"28","author":"Di Lello","year":"2022","journal-title":"World J Gastroenterol"},{"key":"2026021810420176300_ofaf368-B50","doi-asserted-by":"crossref","first-page":"e2120929","DOI":"10.1001\/jamanetworkopen.2021.20929","article-title":"Comparative efficacy of a high-dose vs. standard-dose hepatitis B revaccination schedule among patients with HIV: a randomized clinical trial","volume":"4","author":"Vargas","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026021810420176300_ofaf368-B51","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/QAD.0000000000002085","article-title":"Vaccination with Fendrix of prior nonresponding patients with HIV has a high success rate","volume":"33","author":"Machiels","year":"2019","journal-title":"AIDS"},{"key":"2026021810420176300_ofaf368-B52","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/cid\/ciad201","article-title":"Immunogenicity and safety of hepatitis B virus (HBV) vaccine with a toll-like receptor 9 agonist adjuvant in HBV vaccine-na\u00efve people with HIV","volume":"77","author":"Marks","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026021810420176300_ofaf368-B53","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jama.2024.24490","article-title":"HepB-CpG vs HepB-alum vaccine in people with HIV and prior vaccine nonresponse: the BEe-HIVe randomized clinical trial","volume":"333","author":"Marks","year":"2025","journal-title":"JAMA"},{"key":"2026021810420176300_ofaf368-B54","author":"Marks"},{"key":"2026021810420176300_ofaf368-B55","author":"Ring"},{"key":"2026021810420176300_ofaf368-B56","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.jhep.2022.07.003","article-title":"Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion","volume":"77","author":"Papatheodoridis","year":"2022","journal-title":"J Hepatol"},{"key":"2026021810420176300_ofaf368-B57","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/cid\/ciae500","article-title":"48-week viral suppression rates in people with HIV starting long-acting CAB\/RPV with initial viremia","volume":"80","author":"Hickey","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026021810420176300_ofaf368-B58","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/QAI.0000000000003421","article-title":"Identifying implementation determinants and strategies for long-acting injectable cabotegravir-rilpivirine in people with HIV who are virally unsuppressed","volume":"96","author":"Hickey","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026021810420176300_ofaf368-B59","author":"Rana"},{"key":"2026021810420176300_ofaf368-B60","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/hiv.13647","article-title":"Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable antiretroviral therapy feasiBility Study (JABS)","volume":"25","author":"John","year":"2024","journal-title":"HIV Med"},{"key":"2026021810420176300_ofaf368-B61","first-page":"ciaf120","article-title":"Long-acting injectable HIV therapy outcomes among persons with HIV who have adherence challenges to oral antiretroviral therapy","author":"Hastie","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026021810420176300_ofaf368-B62","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/cid\/ciad116","article-title":"Clinical perspective on HIV care of Ukrainian war refugees in Poland","volume":"76","author":"Parczewski","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026021810420176300_ofaf368-B63","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jiph.2024.02.003","article-title":"Prevalence of infectious diseases, immunity to vaccine-preventable diseases and chronic medical conditions among Ukrainian refugees in Germany\u2014a cross sectional study from the German Network University Medicine (NUM)","volume":"17","author":"Brinkmann","year":"2024","journal-title":"J Infect Public Health"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf368\/63580452\/ofaf368.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/7\/ofaf368\/63580452\/ofaf368.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/7\/ofaf368\/63580452\/ofaf368.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T15:42:12Z","timestamp":1771429332000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf368\/8173806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf368","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,6,30]]},"article-number":"ofaf368"}}